Figure 1From: Combination of suberoylanilide hydroxamic acid with heavy ion therapy shows promising effects in infantile sarcoma cell linesClonogenic Survival after SAHA Treatment. Suberoylanilide hydroxamic acid (SAHA) decreases clonogenic survival in pediatric sarcoma cell lines (KHOS-24OS, A-204) as well as an osteoblast cell line (hFOB 1.19) in a dose-dependent manner.Back to article page